Epithelial tumours of the thymus by Ruffié, P et al.
Epithelial tumours of the thymus, including thymomas and thymic
carcinomas are rare tumours (250 new cases a year). Because of its
anatomic situation and rarity, this cancer poses special problems in
both diagnosis and treatment. Clinical management requires the
input of a multidisciplinary team. These guidelines were validated
in February 2000 and an update is planned for 2001. A new classi-
fication system for thymic tumours was published in 1999. Its
place will be considered in the next update. 
Terminology 
There is no standard terminology, but it is recommended that the
particular characteristics of these tumours are taken into consider-
ation: the term ‘encapsulated’ (65% of cases) or ‘invasive’ (35%
of cases) should be used in preference to benign or malignant
thymoma; the term ‘epithelial tumour of the thymus’ includes the
thymomas and the thymic carcinomas in the same group and
excludes benign epithelial cysts, germ cell epithelial tumours
(such as teratomas or embryonal carcinomas) and intrathymic
parathyroid tumours; the term ‘epithelial tumour of the thymus’
should be used in preference to ‘thymoma’. 
Classification 
There is no standard histological classification. Central review of
the histological slides by a panel of experienced pathologists is
recommended, as well as the routine documentation of any cellular
atypia. The classification of Marino and Muller-Hermelink in a
simplified form (cortical, medullary and mixed) is the most widely
used internationally. It is recommended that this classification is
used in conjunction with the more established classifications such
as those of Verley or Rosai and Levine. 
Staging 
The staging system of Masaoka should be used (standard). The
system of the Thymic Tumour Study Group or that of Regnard can
also be used (option) as they may be better adapted to treatment
strategies. However, these need to be validated against the refer-
ence classification of Masaoka, which should therefore still be
used outside a trial context. 
Diagnosis 
The diagnosis of an epithelial tumour of the thymus is made by
the histological examination of a biopsy obtained by anterior
mediastinotomy (except in the case of an encapsulated tumour
which is usually resectable ‘en mass’ (standard)). In the case of
undifferentiated or lymphocyte-predominant forms, the differential
diagnosis must include Hodgkins lymphoma, non-Hodgkins
lymphoma or a germ cell tumour (standard). For carcinomas of
the thymus, a metastasis from a non-small cell carcinoma must be
excluded. A transparietal needle biopsy is an alternative to ante-
rior mediastinotomy (option). A mediastinoscopy is not recom-
mended as it does not provide adequate access to the anterior
mediastinal space. 
Pretherapeutic assessment 
The standard pretherapeutic investigations are: imaging (chest
X-ray (AP and lateral), thoracic CT scan with high abdominal
cuts), respiratory function tests full blood count and immuno-
electrophoresis of paraproteins to exclude an autoimmune syndrome. 
Optional investigations include: thoracic MRI (instead of CT
scanning) or a venocavogram if infiltration or compression of
vasculature by tumour is suspected; fibreoptic bronchoscopy in
cases of suspicion of compression or invasion of the trachea or
bronchus; electromyography and auto-antibody screen (for acetyl-
choline, antithymus, antistriated muscle) if myasthenia gravis is
suspected. 
Prognostic factors 
The extent of resection and the stage of the disease are the only
factors to have unequivocal prognostic value on multivariate
analysis (standard). 
TREATMENT MODALITIES 
Surgery 
The object is to achieve complete excision of tumour with the
thymus and perithymic fat (standard). Sternotomy is the principle
route of approach (standard). Videothoracoscopy is at present
contraindicated. In advanced stages, the surgery must in all 
cases preserve the integrity of at least the phrenic nerve (standard). 
For very large thymic tumours and/or those extending to the
pleura and/or where a pulmonary resection is likely to be neces-
sary, a bilateral anterior thoracotomy with transverse sternotomy
can be considered (option). For small-volume thymic tumours in
myasthenic patients, a cervicomanubrial approach can be used
(option). In the case of ectopic thymomas a posterolateral thoraco-
tomy can be undertaken (option). 
Radiotherapy 
There is no standard approach. The recommendations for target
volume and dose are as follows. 
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The entire thymic region should be treated including sites of
spread (pericardium, large vessels, pleura, lung parenchyma). The
fields are defined with the help of pre- and postoperative imaging
and also by the operative description and the positioning of 
radio-opaque clips/markers. 
The upper border should be positioned at the level of the
cervicothoracic junction. The lower limit should be the mid
mediastinum, except in the case of ectopic forms. Irradiation of the
supra-clavicular spaces is not recommended as it has not been
shown to be useful (level of evidence C). 
Dose 
Following complete resection, a dose of 50–55 Gy, depending on
the size of the original tumour, the mediastinal structures involved
and the dose that will be delivered to normal tissue. Following incom-
plete resection treatment should be according to conformational
techniques, after consideration of dose–volume histograms both
for planning target volume and for critical organs, in particular the
lung parenchyma and the spinal cord. 
In the absence of neoadjuvant treatment, 50–55 Gy to the target
volume with a boost to 60–65 Gy at the level of any residual
tumour as identified from the operative report and markers left at
the time of operation, should be applied. In the case of a simple
biopsy, a dose of 65 Gy is recommended for the entire target
volume. 
Scheduling 
Nine to 10 Gy weekly in five sessions. It is recommended that
patients be included in therapeutic trials. 
Chemotherapy 
Chemotherapy is indicated for those patients presenting with
metastatic disease (10%), and for patients with local recurrence
or metastases who have already been treated with radiotherapy
(standard). Polychemotherapy appears superior to monotherapy
(level of evidence C). 
The reference combination is the CAP protocol (cyclophos-
phamide/doxorubicin/cisplatin). In stages IIIA and IIIB, the value
of chemotherapy in addition to surgery and radiotherapy has not
been proven. The inclusion of patients in prospective studies is
recommended in order to demonstrate the efficacy of these combi-
nations, particularly in the neoadjuvant setting. 
THERAPEUTIC STRATEGY 
The objective is to achieve complete excision of the tumour with
all the thymus and the perithymic fat. It must be carried out by a
surgeon who is familiar with the diagnostic and therapeutic
constraints of the procedure (standard). Treatment depends on the
stage of the disease and the completeness of resection. It can be
planned around the three existing classifications. 
Stage IA (encapsulated tumour, without invasion of the
capsule) 
Complete resection, no additional treatment (Figure 1). 
Stage IB (encapsulated tumour but with adhesion and/or
suspicion of macroscopic invasion of the capsule) 
Complete resection, postoperative radiotherapy at a dose in the
order of 50 Gy (Figure 1). 
Stage II (tumour with microscopic invasion into capsule,
mediastinal pleura or sub-pleural fat) 
Complete resection, postoperative radiotherapy at a dose in the
order of 50–55 Gy (Figure 2). 
Stage III (tumour with macroscopic invasion to lung,
superior vena cava, pericardium) 
Complete resection (Regnard stage IIIA disease): postoperative
radiotherapy at a dose of at least 55 Gy. Incomplete resection
(GETT stage IIIA, Regnard stage IIIB): postoperative radio-
therapy at 55–60 Gy with a boost to residual tumour as marked by
operative clips. Resection initially impossible (biopsy alone,
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Figure 1 Treatment of stage I carcinoma of the thymus GETT and Regnard stage IIIB disease): neoadjuvant chemo-
therapy followed by resection or radiotherapy. These patients
should be included in therapeutic trials (Figure 2). 
Stage IV disease (mixed population) 
Pleural invasion, completely resected (stage IVA): postoperative
radiotherapy to mediastinum and pleura to a dose of 55 Gy according
to perioperative markers. Pleural invasion not amenable to surgical
excision (Masaoka and GETT stage IVA): neoadjuvant chemo-
therapy followed by surgery and radiotherapy. Pleural invasion with
incomplete surgical excision (Masaoka and GETT stage IVA,
Regnard stage IVB) or distant metastases: chemotherapy then
surgical re-evaluation and/or subsequent radiotherapy (Figure 3). 
FOLLOW-UP 
In the absence of objective data, the frequency of surveillance has
not been clearly defined, but it must be continued for at least
15 years in view of the possibility of very late relapses. The
appearance of signs and symptoms of an autoimmune syndrome,
particularly myasthenia gravis, should result in an early search
for recurrence. 
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Figure 3 Treatment of stage IV disease 
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